Gunnar Tafjord
- Consultant; MD
Publications 2023
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Scand J Urol, 58, 101-108
DOI 10.2340/sju.v58.5923, PubMed 37953521
Publications 2022
Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
Scand J Urol, 56 (3), 214-220
DOI 10.1080/21681805.2022.2056633, PubMed 35506475
Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study
BMC Cancer, 22 (1), 1301
DOI 10.1186/s12885-022-10394-w, PubMed 36510166
Publications 2021
Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
Urol Case Rep, 37, 101648
DOI 10.1016/j.eucr.2021.101648, PubMed 33868933
Publications 2018
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241
Publications 2015
Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Radiat Oncol, 10, 232
DOI 10.1186/s13014-015-0540-3, PubMed 26577452
Publications 2011
Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer
Int J Radiat Oncol Biol Phys, 83 (3), 933-9
DOI 10.1016/j.ijrobp.2011.08.028, PubMed 22138456
Publications 2008
[High dose rate brachytherapy in prostate cancer in Norway]
Tidsskr Nor Laegeforen, 128 (11), 1275-8
PubMed 18511969